Nkarta, Inc. · NASDAQ:NKTX
Nkarta — Investor Presentation (May 2026)
21 slides from Nkarta's investor presentation, May 2026
Slide 1: Pioneering Engineered Natural Killer Cells
Pioneering Engineered Natural Killer Cells Transforming the treatment of autoimmune disease | May 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward‐looking statements, within the meaning of the Private Securities Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may Litigation Reform Act of 1995, regarding future events and the future
Slide 3: Creating a Different Kind of Cell Therapy
Harnessing natural killer (NK) cells to deliver a new approach to cell therapy Creating an off-the-shelf product designed for outpatient dosing in community settings Creating a Different Kind of Cell Therapy Pioneering donor-derived, scalable NK cells to broaden access for autoimmune patients 3
Slide 4: Safely Harnessing NK Cells' Natural Killing Ability
Proprietary humanized CD19 binder Safely Harnessing NK Cells' engineered for optimal target cell killing Natural Killing Ability OX40 costimulatory domain CD3ζ signaling moiety Healthy, pre-screened donors provide off-the-shelf availability Outpatient dosing in community-based CAR health settings No
Slide 5: Challenging the Treatment Paradigm for Autoimmune Disease
Challenging the Treatment Paradigm Factors for Autoimmune Disease Genetic Immunoregulatory Environmental Autoimmune disease driven by pathologic B cells is a major unmet need • Estimated 7 million U.S. patients1 Antibodies Treatment with long-term immune suppression is often inadequate and limited b
Slide 6: Cell Therapy Has Shown the Ability to Bring About Drug-Free Remission in Autoimmune Patients
Cell Therapy Has Shown the Ability to Bring About Drug-Free Transient B-cell suppression Remission in Autoimmune Patients can provide durable disease control • CAR+ cells rapidly eliminated • Post-treatment recovery with naïve B cells may lead to an “immune reset” Drug-free remissions were achieved
Slide 7: Logistical Burdens and Toxicity Have Limited CAR T Cell Therapy's Adoption
Logistical Burdens and Toxicity Have Limited CAR T Cell Therapy's Adoption Autologous CAR T logistical CAR T cell toxicity profile Standard of care therapy and manufacturing challenges creates dependency on for autoimmune disease is hamper accessibility additional specialists predominantly outpatien
Slide 8: CAR NK Cells May Be Ideally Suited to Treat Autoimmune Disease
Off-the-shelf, allogeneic CAR NK cells may offer superior safety and accessibility without compromising clinical activity ✓ Outpatient dosing in community settings ✓ On-demand, off-the-shelf availability for autoimmune patients CAR NK Cells ✓ Limited in vivo expansion means low risk low-grade CRS or
Slide 9: NKX019 CD19 CAR NK
CD19 CAR NK NKX019
Slide 10: NKX019 Exhibits Superior Killing of CD19+ Cells Compared to CAR T Therapy
NKX019 NKX019 Exhibits Superior Killing of CD19+ Cells Compared to CAR T Therapy In vivo Distribution of NKX019 CD19 Expressing Cells (Copies per 100 ng gDNA) NKX019 NKX019 Detection CD19 CAR T EC50 Effector : Target Nkarta, Data on File. NKX019 exhibits superior killing in B cell tumor NK cells tra
Slide 11: NKX019 Clinical Responses Achieved without Increasing Proinflammatory Cytokines
NKX019 Clinical Responses Achieved without Increasing Proinflammatory Cytokines No ICANS or Life-Threatening CRS Observed in Nkarta NKX019 Oncology Study1 CAR T clinical responses are associated with NKX019 does not require serum cytokine elevation significant increases in serum cytokines for CR in
Slide 12: NKX019 Depleted and Reset the B Cell Compartment in NHL Patients
NKX019 Depleted and Reset the B Cell Compartment in NHL Patients Patient samples from NHL trial show that B-cell isotypes are reset after NKX019 effectively eliminates CD19+ cells NKX019 treatment in NHL trial from circulation Naïve B cells (IgM and IgD) class switch after activation to Deep suppres
Slide 13: NKX019 Targets and Kills CD19+ Cells Across Multiple Autoimmune Indications
NKX019 Targets and Kills CD19+ Cells Across Multiple Autoimmune Indications In vitro studies using blood samples from individuals with autoimmune diseases show consistent B cell killing by NKX019 Systemic Lupus Erythematosus Scleroderma Myositis 140 non-LN 140 140 120 120 120 100 100 100 80 80 80 60
Slide 14: NKX019 Ongoing Clinical Trials
ONGOING CLINICAL TRIALS NKX019
Slide 15: NKX019 Trials in Progress
Ntrust-1 Lupus Nephritis & Primary Membranous Nephropathy Ntrust-2 NKX019 Scleroderma, Myositis, ANCA-Associated Vasculitis & Rheumatoid Arthritis CD19 CAR NK Trials in Progress Investigator-Sponsored Trial Systemic Lupus Erythematosus Investigator-Sponsored Trial Myasthenia Gravis 15
Slide 16: Cohesive Study Objectives Across NKX019 Clinical Trials
Cohesive Study Objectives Across NKX019 Clinical Trials Primary Secondary Exploratory Safety and tolerability Clinical activity, Autoantibodies, of NKX019 in the treatment immunogenicity and pharmacodynamics of B-cell mediated pharmacokinetics and cytokine profile autoimmune diseases 16
Slide 17: NKX019 Treatment Schema
NKX019 Treatment Schema Dose escalation to 4B CAR+ NK cells per dose • Outpatient administration enables expanded treatment in community settings • Redosing option (if needed) to deepen or restore patient response NKX019 – 3 doses per cycle Lymphodepletion -5 -4 -3 Disease Day 0 Day 3 Day 7 assessme
Slide 18: Ntrust-1: Phase 1 Clinical Trial
Ntrust-1: Phase 1 Clinical Trial Patients with refractory lupus nephritis (LN) or primary membranous nephropathy (pMN) Key Eligibility: Adults (18-75 yo) who have tried standard of care and still have active disease with proteinuria LN pMN US prevalence: ~60,000 US prevalence: ~30,000 2019 ACR Crite
Slide 19: Ntrust-2: Phase 1 Clinical Trial
Ntrust-2: Phase 1 Clinical Trial Patients with refractory systemic sclerosis (SSc), inflammatory myopathy (IM), ANCA-associated vasculitis (AAV) and rheumatoid arthritis (RA) Key Eligibility: Adults (18-65 yo) who have tried standard of care and still have active or progressive disease SSc IM AAV RA
Slide 20: Investigator-Sponsored Trials
Investigator-Sponsored Trials Patients with refractory systemic lupus erythematosus (SLE) and myasthenia gravis (MG) SLE with or without lupus nephritis MG US prevalence: ~200,000 US prevalence: ~100,000 SLEDAI Criteria MGFA Class II-IV disease Class III, IV, +/- V LN by renal biopsy AChR and/or MuS
Slide 21: Summary
Summary Several indications Data updates from Cash runway Focused on clinical being evaluated in the Ntrust-1 and Ntrust-2 into 2029 to enable trial execution clinic to allow multiple expected at medical achievement of shots on goal meeting in 2026 clinical milestones